Important Safety Information Prescribing Information Patient Site Request an Account Manager
Eye care professional examining a patient

Designed with
comfort in mind

Start them off smart

Qlosi supports first-line use through a tolerability-focused design1-4

When patients trust the drop,
they stay on the drop.
This table does not reflect a head-to-head study of Qlosi, VUITY®, VIZZ™, or YUVEZZI™.
Concentration of Primary Active
Common Adverse Reactions*
Non-ocular AEs
Headache
Ocular AEs
Instillation site pain/irritation
Blurred vision
Visual impairment
Conjunctival hyperemia
Ocular hyperemia
QLOSI1,4
(0.3% pilocarpine)
N=308
0.4%
Pilocarpine HCl
21 (6.8%)
4.8% moderate
18 (5.8%)
11 (3.6%)
3 (1.0%)
5 (1.6%)
–
VUITY®5-7
(1.06% pilocarpine)
N= 375
1.25%
Pilocarpine HCl
56 (14.9%)
16% moderate or severe
16 (4.3%)
17 (4.5%)
10 (2.7%)
19 (5.1%)
–
VUITY PI
VIZZ™8,9*
(1.44% aceclidine)
N=234
1.75%
Aceclidine HCl
30 (13%)
4% severe, 7% moderate
47 (20%)
–
37 (16%)†
19 (8%)
16 (7%)
VIZZ PI
YUVEZZI™10,11
(2.75% carbachol / 0.1% brimonidine tartrate)
N=536
2.75% Carbachol /
Brimonide Tartrate
36 (15.6%)
32 (14%) irritation
15 (6.7%) eye pain
–
14 (6.4%)
6 (2.8%)
(hyperemia)
YUVEZZI PI
VIZZ™ is a trademark of LENZ Therapeutics, Inc. VUITY® is a registered trademark of AbbVie Inc. YUVEZZI™ is a trademark of Visus Therapeutics, Inc.

*Most common adverse reactions defined as adverse reactions reported in ≥5% of patients.

†Dim vision reported.

AEs=adverse events

  • In clinical studies, most patients did not experience side effects1
  • When they did, they were typically mild and transient1
  • The most common were eye discomfort and headache1
“Very comfortable”

→ Presbyopia patients within 10 minutes
of administering Qlosi on Days 1, 8, and 154

Dr. Brian Brightman
“
I tell my doctor friends that haven’t tried Qlosi yet, don’t be afraid to use it. With the adjusted pH and the comfort and tolerability, it’s a night and day different experience for the patient.”

→ Dr. Brian Brightman, OD Lincoln, NE

Dr. Leslie Scher
“
I really became a Qlosi fanatic when I saw all the safety data. With such a low concentration, I truly do feel safe giving my patients that option. I also love that it’s preservative free. I think that’s so important.”

→ Dr. Leslie Scher, OD Miami, FL

Clara T.
“
Drops they dread don’t stick.
Drops they love? That’s Qlosi”

Indication and Usage

Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%, for topical ophthalmic use is a cholinergic receptor agonist indicated for the treatment of presbyopia in adults.

Important Safety Information

Contraindications

Hypersensitivity

Warnings and Precautions

Advise patients to not drive or operate machinery if vision is not clear (e.g., blurred vision). Exercise caution in night driving and other hazardous occupations in poor illumination.

Rare cases of retinal detachment have been reported with miotics. Examination of the retina is advised in all patients prior to initiation of therapy. Advise patients to seek immediate medical care with sudden onset of flashes of lights, floaters, or vision loss.

Qlosi is not recommended to be used when iritis is present.

Qlosi should not be administered while wearing contact lenses. Remove lenses prior to the instillation of Qlosi and wait 10 minutes before reinsertion.

Avoid touching the tip of the vial to the eye or any other surface.

Adverse Reactions

The most common adverse reactions (5% to 8%) are instillation site pain and headaches.

Please see full Prescribing Information here: qlosiecp.com/prescribing-information

References

  1. Qlosi [package insert]. Ponte Vedra, FL. Orasis Pharmaceuticals.
  2. Anderson RA, Cowle JB. Influence of pH on the effect of pilocarpine on aqueous dynamics. Br J Ophthalmol. 1968;52(8):607-611. doi:10.1136/bjo.52.8.607
  3. Mitra AK, Mikkelson TJ. Mechanism of transcorneal permeation of pilocarpine. J Pharm Sci. 1988;77(9):771-775. doi:10.1002/jps.2600770911
  4. Holland E, Karpecki P, Fingeret M, et al. Efficacy and safety of CSF-1 (0.4% pilocarpine hydrochloride) in presbyopia: pooled results of the NEAR phase 3 randomized, clinical trials. Clin Ther. 2024;46(2):104-113. doi:10.1016/j.clinthera.2023.12.005
  5. Waring GO, Price FW, Wirta D. Safety and efficacy of AGN-190584 in individuals with presbyopia: the GEMINI 1 phase 3 randomized clinical trial. JAMA Ophthalmol. 2022;140(4):363-371. doi:10.1001/jamaophthalmol.2022.0059
  6. VUITY PI [package insert]. North Chicago, IL: AbbVie Inc.
  7. Waring GO, Moshirfar M, Lievens CW, Liu H, Zheng S, Robinson MR. Twice- vs once-daily pilocarpine HCl 1.25% for presbyopia: safety profile from randomized, masked, controlled, prospective phase 3 studies. Poster presented at the American Society of Cataract Surgery (ASCRS) annual meeting; May 5-8, 2023; San Diego.
  8. VIZZ PI [package insert]. Solano Beach, CA: LENZ Therapeutics, Inc.
  9. LENZ Therapeutics Corporate Presentation. Available at: https://ir.lenz-tx.com/news-events/presentations. Accessed November 17, 2025.
  10. Yuvezzi. Prescribing information. Visus Therapeutics, Inc; 2025.
  11. RO Staff. First dual-agent drop approved for presbyopia. Review of Optometry. Published January 29, 2026. Accessed June 3, 2026. https://www.reviewofoptometry.com/article/first-dualagent-drop-approved-for-presbyopia